Loading viewer...
investor_presentation
Format: PDF investor_presentation
Verona Pharma presents ensifentrine, a Phase 3 first-in-class inhaled PDE3/PDE4 inhibitor candidate for COPD maintenance treatment. The company targets a ~$10.5B US market with over 1 million symptomatic patients despite existing dual/triple therapies, highlighting significant unmet medical need and commercial opportunity.
investor_presentation
27 Pages
investor_presentation
41 Pages
Coventry Group Ltd
investor_presentation
Energen
investor_presentation
Indosat Ooredoo